Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 8 of 16
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
NCT03328091
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT03294694
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
NCT03289039
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
NCT03225716
Nivolumab Plus Ipilimumab in Thyroid Cancer
NCT03246958
Post-Operative Ambulatory Challenge and Exercise (PACE) Trial
NCT03234933
Cyclophosphamide and Alemtuzumab In Lymphoma
NCT03132584
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
NCT03093272
Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study
NCT03170648
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
NCT03131206
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
NCT03093428
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
NCT03101254
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
NCT03170206
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
NCT03130439
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
NCT03051672
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT03087019
The HOPE Trial and the SMART Study
NCT03022032
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT03075527
Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors
NCT02848989
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
NCT02865135
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
NCT03051659
Reduction of Post Mastectomy Pain With the Jacki® Recovery Jacket
NCT02976103
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT03032107
Improving Communication Between Cancer Patients & Oncologists
NCT02969031
CISPLATIN + AZD-1775 In Breast Cancer
NCT03012477
Pembrolizumab in Refractory Advanced Esophageal Cancer
NCT02971956
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
NCT02581384
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
NCT02867384
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
NCT02956473
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
NCT02920996
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
NCT02903381
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
NCT02903368
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
NCT02873975
Pembrolizumab in Metastatic Anal Cancer
NCT02919969
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
NCT02916771
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
NCT02909777
A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
NCT02919670
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
NCT02865811
Palbociclib With Everolimus + Exemestane In BC
NCT02871791
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
NCT02724878
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
NCT02661815
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
NCT02795858
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
NCT02770014
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
NCT02677324
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
NCT02698891
Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
NCT02706249
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
NCT02657343
Gut Decontamination In Pediatric Allogeneic Hematopoietic
NCT02641236
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
NCT02499497
Novel Social Media Intervention For Older Br CA Patients
NCT02639208
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.